Inozyme Pharma Appoints Petra Duda As Chief Medical Officer

May 15, 2025•7 months ago

Position

Chief Medical Officer

Company

Inozyme Pharma

Petra Duda

BostonTherapeuticsPharmaceuticalHealth Care

Description

Inozyme Pharma has appointed Petra Duda as its new Chief Medical Officer, succeeding the retiring Kurt Gunter. Dr. Duda brings over two decades of experience in global clinical development and regulatory leadership to the role.

Company Information

Company

Inozyme Pharma

Location

Boston, Massachusetts, United States

About

Inozyme Pharma is a USA-based biopharma company focused on developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. The company aims to address significant unmet needs in patients suffering from these conditions. Inozyme is publicly traded on Nasdaq under the ticker INZY.

Related People

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months

Inozyme Pharma Appoints Petra Duda As Chief Medical Officer

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Executive Insights

Company Information